Company Overview of Protein Sciences Corporation
Protein Sciences Corporation develops, manufactures, and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers Flublok, a recombinant protein-based seasonal influenza vaccine; Panblok, a pandemic influenza vaccine; FluNhance that is used to enhance additive to influenza vaccines; and SARS (D3252), a Severe Acute Respiratory Syndrome vaccine that is used to elicit neutralizing antibodies to the virus. It also provides Baculovirus Expression Vector System, a platform technology used for the development of a range of vaccines and therapeutics, such as prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applica...
1000 Research Parkway
Meriden, CT 06450
Founded in 1983
Key Executives for Protein Sciences Corporation
Chief Executive Officer, President and Director
Chief Administrative Officer, Senior Vice President and Corporate Secretary
Senior Vice President of Manufacturing Operations
Senior Vice President of Quality
Compensation as of Fiscal Year 2016.
Protein Sciences Corporation Key Developments
Protein Sciences Zika Vaccine Shows Good Results in Preclinical Testing
Jan 12 17
Protein Sciences Corporation announced that its lead protein based Zika vaccine candidate had good safety results and induced strong neutralizing antibodies against the Zika virus in preclinical studies. The product is expected to advance into human clinical trials in the next few months. In addition, the Institute of Technology in Immunobiologicals of the Oswaldo Cruz Foundation (Bio-Manguinhos/Fiocruz), has joined the multinational consortium that is sponsoring development of the vaccine. The vaccine candidate is composed of purified protein that matches a protein found on the outer surface of the Zika virus (the E protein) and was created using Protein Sciences' proprietary BEVS technology because of its speed, safety and ability to accurately match the field virus. In preclinical testing, the purified protein formulated with alum induced strong levels of neutralizing antibodies in outbred mice, which is a positive indicator that the vaccine will protect against Zika virus infection. In addition, the vaccine candidate demonstrated good safety data in a toxicology study sponsored by National Institute of Allergy and Infectious Disease, National Institutes of Health through its pre-clinical support program. Based on these data, preparations are being made to start a Phase I clinical study in the United States in April 2017.
Protein Sciences to Launch its New Influenza Vaccine Flublok in October at the Mexican Market
Oct 12 16
Protein Sciences announced that it would launch its new influenza vaccine Flublok in the Mexican market this month. The product is expected to be 40% more effective than other competing products in the market, and is free of preservatives, gluten, and latex. The vaccine is indicated for patients aged 18 years and older, and its paediatric usage is currently being analysed. According to Protein Sciences, Flublok will be sold in the country by Mexican firm Liomont until 2030. Liomont first announced in November 2015 plans to launch Flublok in Mexico as a result of a licensing agreement. Flublok is produced by Sanofi Pasteur, the vaccine division of the French manufacturer Sanofi. The US FDA approved Flublok in 2013 for people aged between 18 and 49 years. It is a novel trivalent vaccine manufactured with recombinant DNA technology using an insect virus (baculovirus). It contains haemagglutinin antigens of H1N1, H3N2, and type B flu viruses. The flu virus or chicken eggs are not used in the production of Flublok.
FDA Approves Flublok® Quadrivalent Influenza Vaccine
Oct 11 16
Protein Sciences Corporation announced that the FDA has approved its quadrivalent formulation of Flublok® influenza vaccine. Flublok Quadrivalent protects against 4 strains of influenza, 3 of the same strains found in trivalent Flublok plus an additional B strain. Significantly, Flublok Quadrivalent is the first and only high antigen content quadrivalent flu vaccine approved by FDA. It contains 3x more active ingredient than all other quadrivalent vaccines, making it a great choice for seniors and those with compromised immune systems, among others. In a clinical study of 9,000 adults 50 years of age and older, people who received Flublok Quadrivalent were over 40% less likely to get cell-culture confirmed influenza than those that received a leading egg-produced quadrivalent flu vaccine. These results are relevant for trivalent Flublok, as the H3N2 component of the vaccine that is shared between trivalent and Flublok Quadrivalent predominately contributed to the improved efficacy. Flublok Quadrivalent is approved for adults 18 and older and will be available in pre-filled syringes beginning in 2017. Flublok Quadrivalent has the same purity advantages as trivalent Flublok, containing pure protein made without infectious influenza virus, antibiotics, eggs, thimerosal, preservatives, gelatin or latex.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|